Medline Inc. (MDLN) financials
NASDAQ · Healthcare · Medical - Instruments & Supplies · 45,000 employees · CEO James Boyle
- Price
- $37.55 0.0%
- Market cap
- $32.5B
- Enterprise value
- $42.8B Data as of 2026-11-22
- Last report
- Q3 '26 filed 2026-11-04
- Next report
- 2027-02-24 EPS est. $0.39
Valuation & key figures
- Market cap
- $32.5B Updated 1h ago
- Revenue
- $30.7B Trailing 12 months
- Revenue growth
- +10% FY2026 consensus
- Profit margin
- 1.8% Net income / revenue, TTM
- P/E
- 55.3× Forward 24.2× (FY2026)
- P/S
- 1.1× Price / sales, TTM
- EV / EBITDA
- 16.4× TTM
- Free cash flow
- $1.9B Trailing 12 months
- Net income
- $564M Trailing 12 months
- Revenue estimate
- $31.4B FY2026 consensus
- Earnings
- 2027-02-24 Revenue est. $8.5B · Updated 1h ago
- Dividend
- – No dividend
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-11-04): revenue beat by 1.7%, EPS beat by 28.2%Revenue $7.86B vs $7.72B expected (+1.7%); EPS $0.44 vs $0.34 (+28.2%).
- Revenue growth steady: 10.4% year on yearQ3 '26 revenue $7.86B, against an average of 11.2% over the four quarters before.
- 55.8% of pre-tax profit is eaten by non-operating lossesPre-tax income $1.12B vs operating income $1.74B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
- Capex 1.6% of revenue$486M invested in the last 4 quarters (– on a year earlier). Free cash flow $1.9B = 336.0% of net income.
- Returned $2.07B to shareholders = 109.0% of free cash flowBuybacks $1.97B (a year earlier –), dividends $96M, stock-based pay $81M (TTM). More than the free cash flow: paid from cash or debt.
- Diluted share count up 67.2% in a year1.32B diluted shares in Q3 '26, 787M a year earlier.
- Net debt $8.97BCash + short-term investments $3.61B, debt incl. leases $12.6B; a year ago net debt $15.7B.
Last quarter: Q3 '26
Quarter ended 2026-09-26. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q3 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $7.86B | $7.12B | +10.4% |
| Gross margin | 24.5% | 23.9% | +0.6 pp |
| Operating income | $500M | $574M | -12.9% |
| Operating margin | 6.4% | 8.1% | -1.7 pp |
| Net income | $195M | $322M | -39.4% |
| Diluted EPS | $0.22 | $0.41 | -46.3% |
| Operating cash flow | $1.03B | $636M | +61.2% |
| Capex | $141M | $101M | +39.6% |
| Free cash flow | $884M | $535M | +65.2% |
| R&D | $0 | $0 | – |
| Stock-based compensation | $52M | $0 | – |
Reported vs consensus
2026-11-04| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $7.86B | $7.72B | +1.7% |
| EPS (as estimated) | $0.44 | $0.34 | +28.2% |
From the report of 2026-11-04 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by region
share of the listed regions| Segment | Q3 '26 | y/y | Share of listed | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| United States | $7.34B | – | 93.4% | – | – | |
| Non-US | $518M | – | 6.6% | – | – |
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- $2.38B
- Capex
- -$486M
- Buybacks
- -$1.97B
- Dividends
- -$96M
- Acquisitions
- $0
- Net debt issued
- -$4.09B
- Stock-based compensation
- $81M
- Free cash flow
- $1.9B
- Returned to shareholders / FCF
- 109.0%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | 55.3× | 64.3× 3 of 4 years | 27.0× – 136.7× |
| EV / EBITDA | 16.4× | 18.3× 3 of 4 years | 15.0× – 20.2× |
| EV / Sales | 1.4× | 1.8× 3 of 4 years | 1.6× – 2.0× |
| Price / FCF | 17.2× | 24.1× 3 of 4 years | 22.9× – 26.3× |
| Price / Book | 2.8× | 2.3× 3 of 4 years | 1.9× – 3.2× |
| FCF yield | 5.8% | 3.1% | -0.2% – 4.4% |
| Return on invested capital | 3.7% | 3.8% | 0.0% – 6.1% |
| Return on equity | 5.0% | 4.9% | 0.0% – 10.8% |
Analysts
Consensus target $44.20 (+19.3%)
range $37.00 – $55.00 · rating Buy
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $31.4B | +10.4% | $1.55 | +8.6% | 24.2× | 13 |
| FY2027 | $34B | +8.2% | $1.57 | +0.9% | 24.0× | 14 |
| FY2028 | $36.7B | +8.0% | $1.76 | +12.5% | 21.3× | 8 |
| FY2029 | $39.5B | +7.8% | $2.02 | +14.8% | 18.6× | 5 |
| FY2030 | $42.5B | +7.6% | $2.25 | +11.3% | 16.7× | 5 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 324 figures Medline Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $1.21B | – | – | $961M | $869M | +10.6% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $3.79B | – | – | $3.53B | $3.22B | +9.8% |
| Accounts Receivable, Allowance for Credit Loss, Current | $148M | – | – | $152M | $108M | +40.7% |
| Accounts Receivable, Credit Loss Expense (Reversal) | $4M | $6M | -33.3% | $54M | $63M | -14.3% |
| Accrual for Taxes Other than Income Taxes | $82M | – | – | $87M | $83M | +4.8% |
| Accrued Income Taxes, Current | $16M2026-06-27 | – | – | $24M | $4M | +500.0% |
| Accrued Liabilities, Current | $1.89B | – | – | $1.45B | $1.49B | -2.7% |
| Accrued Salaries, Current | $483M | – | – | $323M | $330M | -2.1% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $1.16B2025-12-31 | $861M | +34.8% | $1.16B | $861M | +34.8% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$4M | – | – | $27M | $11M | +145.5% |
| Additional Paid in Capital | $11.4B | – | – | $10.7B | – | – |
| Amortization of Debt Issuance Costs | $10M | $15M | -33.3% | $59M | $57M | +3.5% |
| Amortization of Intangible Assets | $176M | $177M | -0.6% | $704M | $685M | +2.8% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2.22M | – | – | – | – | – |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $29M | – | – | – | – | – |
| Asset Impairment Charges | – | – | – | $0 | – | – |
| Assets | $40.2B | – | – | $38.5B | $36B | +7.0% |
| Assets, Current | $12.7B | – | – | $10.7B | $8.27B | +29.1% |
| Assets, Fair Value Disclosure | $1.3B | – | – | – | – | – |
| Business Combination, Contingent Consideration, Liability | $29M | – | – | – | – | – |
| Capital Expenditures Incurred but Not yet Paid | -$24M | -$22M | -9.1% | $58M | $50M | +16.0% |
| Cash and Cash Equivalents, at Carrying Value | $2.32B | – | – | $1.94B | $199M | +874.4% |
| Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months | -$9M | – | – | $34M | – | – |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $2.32B | $955M | +143.2% | $1.94B | $250M | +676.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$6M | $371M | -101.6% | $1.69B | -$1.34B | +226.7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $124M | $0 | – | -$2M | $0 | – |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $197M | $312M | -36.9% | $1.19B | $1.02B | +16.4% |
| Cost of Goods and Services Sold | $5.93B | $5.24B | +13.2% | $20.9B | $18.5B | +12.9% |
| Current Federal Tax Expense (Benefit) | – | – | – | $24M | $6M | +300.0% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $83M | $58M | +43.1% |
| Current Income Tax Expense (Benefit) | – | – | – | $111M | $70M | +58.6% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $4M | $6M | -33.3% |
| Debt Issuance Costs, Net | $164M | – | – | $195M | $265M | -26.4% |
| Debt, Current | $29M | – | – | $77M | $78M | -1.3% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $4M | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$24M | -$24M | 0.0% |
| Deferred Income Tax Assets, Net | $833M | – | – | $583M | $0 | – |
| Deferred Income Tax Expense (Benefit) | $39M | -$3M | +1,400.0% | -$20M | -$24M | +16.7% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Tax Asset, Interest Carryforward | $142M2025-12-31 | $0 | – | $142M | $0 | – |
| Deferred Tax Assets, Net | $384M2025-12-31 | – | – | $384M | – | – |
| Deferred Tax Assets, Net of Valuation Allowance | $747M2025-12-31 | $28M | +2,567.9% | $747M | $28M | +2,567.9% |
| Deferred Tax Assets, Other | $8M2025-12-31 | $4M | +100.0% | $8M | $4M | +100.0% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $14M2025-12-31 | $13M | +7.7% | $14M | $13M | +7.7% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $17M2025-12-31 | $10M | +70.0% | $17M | $10M | +70.0% |
| Deferred Tax Assets, Valuation Allowance | $215M | – | – | $0 | $1M | -100.0% |
| Deferred Tax Liabilities, Gross | $363M2025-12-31 | $223M | +62.8% | $363M | $223M | +62.8% |
| Deferred Tax Liabilities, Intangible Assets | $170M2025-12-31 | $183M | -7.1% | $170M | $183M | -7.1% |
| Deferred Tax Liabilities, Inventory | $02025-12-31 | $1M | -100.0% | $0 | $1M | -100.0% |
| Deferred Tax Liabilities, Investments | $157M2025-12-31 | $0 | – | $157M | $0 | – |
| Deferred Tax Liabilities, Net | – | – | – | $195M2024-12-31 | – | – |
| Deferred Tax Liabilities, Other | $2M2025-12-31 | $2M | 0.0% | $2M | $2M | 0.0% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $34M2025-12-31 | $37M | -8.1% | $34M | $37M | -8.1% |
| Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate | 7.4%2025-12-31 | 7.0% | +5.9% | 7.4% | 7.0% | +5.9% |
| Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase | 4.5%2025-12-31 | 4.4% | +3.2% | 4.5% | 4.4% | +3.2% |
| Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate | – | – | – | 7.0% | 6.3% | +11.5% |
| Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets | – | – | – | 3.3% | 3.5% | -5.8% |
| Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase | – | – | – | 4.4% | 4.3% | +0.2% |
| Defined Benefit Plan, Benefit Obligation | $61M2025-12-31 | $49M | +24.5% | $61M | $49M | +24.5% |
| Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years | $42M2025-12-31 | – | – | $42M | – | – |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-26, 10-Q 2026-06-27, 10-Q 2026-03-28, 10-K 2025-12-31
Data as of 2026-11-22